5-chloro-1,4-dihydro-6,7-dihydroxy-1-ethyl-4-oxoquinoline-3-carboxylic acid | 80104-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-chloro-1,4-dihydro-6,7-dihydroxy-1-ethyl-4-oxoquinoline-3-carboxylic acid
• 英文别名: 5-chloro-6,7-dihydroxy-1,4-dihydro-1-ethyl-4-oxoquinoline-3-carboxylic acid；5-chloro-1-ethyl-6,7-dihydroxy-4-oxo-1,4-dihydroquinolin-3-carboxylic acid；5-chloro-1-ethyl-6,7-dihydroxy-4-oxoquinoline-3-carboxylic acid
• CAS: 80104-60-5
• 化学式: C₁₂H₁₀ClNO₅
• 分子量: 283.668
• InChiKey: WMTLPJOHVWWFSD-UHFFFAOYSA-N

物化性质

• 熔点：
  264-266 °C (decomp)
• 沸点：
  572.6±50.0 °C(Predicted)
• 密度：
  1.632±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  98.1
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-chloro-1,4-dihydro-6,7-dihydroxy-1-ethyl-4-oxoquinoline-3-carboxylic acid 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 5-Chloro-1-ethyl-4-oxo-6,7-bis-trimethylsilanyloxy-1,4-dihydro-quinoline-3-carbonyl chloride
  参考文献：
  名称：

  Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model

  摘要：

  Two series of cephalosporins A and B have been synthesized, bearing at C-3' catechols substituted with various electron withdrawing groups (Y) and differing links (X), and were evaluated for their in vitro antibacterial activity and their pharmacokinetics in marmosets. Compounds in series A, bearing an isobutyric oxime substituent, proved to be highly active against Gram-negative organisms and were especially noteworthy for showing long elimination phase (beta) half-lives in marmosets. It was established that introduction of electron withdrawing substituents greatly increased the beta-half-lives of compounds (5, X = NHCO, Y = H, t1/2 = 1.25 h, AUC = 27 mg/h per L; 11, X = NHCO, Y = 5-Cl, t1/2, = 4.5 h, AUC = 638 mg/h per L) and that the nature of the link also influenced t1/2, the highest values being obtained when X = NHCO and OCO. Acidities (pK(a) values) of the substituted catechols were measured, and relationships between the acidities and half-lives were evaluated. Thus it was established that the more acidic catechols gave the longest half-lives (12, X = NHCO, Y = 2,5-Cl2, t1/2 = 8.2 h, AUC = 461 mg/h per L). Further elaboration of the catechol to bicyclic systems maintained good pharmacokinetics when the pK(a) was sufficiently acidic.

  DOI：

  10.1021/jm00092a015
• 作为产物：
  描述：

  9-amino-5-ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-g]quinolin-7-carboxylic acid 在 盐酸 、 硫酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 17.0h， 生成 5-chloro-1,4-dihydro-6,7-dihydroxy-1-ethyl-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  4-喹诺酮-5-重氮盐的一些反常反应

  摘要：

  5-氨基官能团在6，7-烷氧基-1-乙基-1，4-二氢-4-氧代喹啉-3-羧酸中的重氮化反应产生了各种产物。脱重氮总是伴随着6-烷氧基取代基的裂变。6,7-亚甲二氧基团，得到甲醛能构成米-dioxino环。重氮氯化物的水解导致卤素脱重氮。

  DOI：

  10.1002/jhet.5570180528

文献信息

• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：GLAXO GROUP LTD

  公开号：WO2013052568A1

  公开（公告）日：2013-04-11

  The present Invention relates to cephalosporin antibacterial compounds of Formula (!): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

  本发明涉及头孢菌素抗菌化合物的公式（I）：以及相应的药学上可接受的盐、相应的药物组合物、化合物制备和治疗细菌感染的方法，特别是由革兰氏阴性细菌引起的感染。
• ANTIBACTERIAL COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：US20140249126A1

  公开（公告）日：2014-09-04

  The present invention relates to cephalosporin antibacterial compounds of Formula (I): or corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

  本发明涉及式（I）的头孢菌素抗菌化合物：或其相应的药学上可接受的盐，相应的制药组合物，化合物制备和治疗细菌感染的方法，特别是由革兰氏阴性菌引起的感染。
• Antibacterial compounds
  申请人：GLAXO GROUP LIMITED

  公开号：US09340556B2

  公开（公告）日：2016-05-17

  The present invention relates to cephalosporin antibacterial compounds of Formula (I): or corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

  本发明涉及公式(I)的头孢菌素抗菌化合物，或其相应的药学上可接受的盐，相应的药物组成，化合物制备和治疗细菌感染的方法，尤其是由革兰氏阴性菌引起的感染。
• FRANK, J.;RAKOCZY, P.;RADICS, L.;GACS-BAITZ, E., J. HETEROCYCL. CHEM., 1981, 18, N 5, 985-990
  作者：FRANK, J.、RAKOCZY, P.、RADICS, L.、GACS-BAITZ, E.

  DOI：——

  日期：——
• US5019570A
  申请人：——

  公开号：US5019570A

  公开（公告）日：1991-05-28